Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merdeka Battery Materials Tbk. (MBMA) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance

Merdeka Battery Materials Tbk.Trade
Organon Pharma Indonesia Tbk.Trade

Price performance (Past 24H)

Key statistics

Merdeka Battery Materials Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Merdeka Battery Materials Tbk. trades at Rp520 (market cap 57.24T, 89.37M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Merdeka Battery Materials Tbk. is far larger — about 548.3× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.

MBMASCPI
Market Cap
57.24T104.4B
Volume
89.37M
Lot
893.72K
Turnover
46.3B
Average Price
518.08
Value
46.3B
Indicative Equilibrium Price
520
Indicative Equilibrium Volume
90.42K

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MBMA
View details
SCPI
View details

About Merdeka Battery Materials Tbk.

PT Merdeka Battery Materials Tbk (formerly PT Hamparan Logistik Nusantara) (the “Company”) was established based on Notarial Deed No. 66 of Darmawan Tjoa, S.H., S.E., Notary in Jakarta, dated 20 August 2019. The Company’s immediate parent entity is PT Merdeka Energi Nusantara (formerlyPT Batutua Tambang Abadi) (“MEN”) and its ultimate parent entity is PT Merdeka Copper Gold Tbk (“MDKA”), a company incorporated in Indonesia and listed on the Indonesian Stock Exchange (“IDX”).

Read more on MBMA

About Organon Pharma Indonesia Tbk.

PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.

Read more on SCPI